## **DOCKET** A L A R M Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

AstraZeneca and our year in brief01Financial highlights02Chairman's statement04Chief Executive Officer's review05DIRECTORS' REPORT08Goals, strategy and99Business environment13Business organisation17> Board of Directors at 31 December 200718> Chief Executive Officer, delegation of authority and Senior Executive Team20Our resources, skills and capabilities21> Medicines21> Research and development23> Research and development23> Development pipeline at 31 January 200828> Sales and marketing31> Intellectual property33> People35> Main facilities37Corporate governance and managing risk38Cardiovascular (CV) medicines50Gastrointestinal (GI) medicines50Respiratory and Inflammation (R&I) medicines73Infection medicines66Other businesses68Geographical review75Financial review77> Business background and major events affecting 200778> Results of operations – summary analysis of year to 31 December 200778> Financial position, including cash flow and liquidity81> Acquisition of MedImmune83> Results of operations – summary analysis of year to 31 December 200778> Financial position, including cash flow and liquidity81<	INTRODUCTION	01
Financial highlights02Chairman's statement04Chief Executive Officer's review05DIRECTORS' REPORT08Goals, strategy and9Business environment13Business organisation17> Board of Directors at atthority and Senior Executive Team20Our resources, skills and capabilities21> Medicines21> R&D governance and portfolio management27> Development pipeline att 31 January 200828> Sales and marketing31> Intellectual property33> Supply and manufacturing33> Supply and manufacturing33> People35> Main facilities37Corporate governance and managing risk38Cardiovascular (CV) medicines50Gastrointestinal (GI) medicines50Oncology medicines60Oncology medicines63Infection medicines63Geographical review71> Measuring performance77> Business background and mailysis of year to 31 December 200778Pinancial position, including cash flow and liquidity81> Acquisition of MedImmune83> Results of operations – summary analysis of year to 31 December 200778> Financial position, including cash flow and liquidity81> Acquisition of MedImmune84> Financial review78> Suppli and shareholder return84> Capitalisation		
Chairman's statement04Chief Executive Officer's review03DIRECTORS' REPORT08Goals, strategy and99Business environment13Business organisation17> Board of Directors at 31 December 200718> Chief Executive Officer, delegation of authority and Senior Executive Team20Our resources, skills and capabilities21> Medicines21> R&D governance and portfolio management27> Development pipeline at 31 January 200828> Sales and marketing31> Intellectual property33> People35> Main facilities37Corporate governance and managing risk38Cardiovascular (CV) medicines50Gastrointestinal (GI) medicines53Neuroscience medicines66Oncology medicines63Infection medicines66Other businesses68Geographical review77> Business background and major events affecting 200778> Financial performance77> Business background and major events affecting 200778> Financial position, including cash flow and liquidity81> Acquisition of MedImmune83> Resurts of operations – summary analysis of year to 31 December 200778> Financial review77> Business background and major events affecting 200778> Financial position, including cash flow and liquidity81 <td></td> <td>• •</td>		• •
Chief Executive Officer's reviewOfDIRECTORS' REPORT08Goals, strategy and99Business environment13Business organisation17> Board of Directors at 31 December 200718> Chief Executive Officer, delegation of authority and Senior Executive Team20Our resources, skills and capabilities21> Medicines21> Research and development23> R&D governance and portfolio management27> Development pipeline at 31 January 200828> Sales and marketing31> Intellectual property33> Supply and manufacturing33> People35> Main facilities37Corporate governance and managing risk38Cardiovascular (CV) medicines50Gastrointestinal (GI) medicines50Gastrointestinal (GI) medicines63Infection medicines66Other businesses68Geographical review75Financial review77> Measuring performance77> Business background and major events affecting 200778> Results of operations – summary analysis of year to 31 December 200779> Financial position, including cash flow and liquidity81> Acquisition of MedImmune83> Results of operations – summary analysis of year to 31 December 200779> Financial position, including cash flow and liquidity81> Acquisition of MedImmune <td< td=""><td></td><td></td></td<>		
DIRECTORS' REPORT08Goals, strategy and performance measurement09Business environment13Business organisation17> Board of Directors at 31 December 200718> Chief Executive Officer, delegation of authority and Senior Executive Team20Our resources, skills and capabilities21> Medicines21> Research and development23> R&D governance and portfolio management27> Development pipeline at 31 January 200828> Sales and marketing31> Intellectual property33> People35> Main facilities37Corporate governance and managing risk38Cardiovascular (CV) medicines50Gastrointestinal (GI) medicines53Neuroscience medicines66Other businesses68Geographical review69In the global community73Environmental review77> Measuring performance77> Business background and major events affecting 200778Pasults of operations – summary analysis of year to 31 December 200779> Financial position, including cash flow and liquidity81> Acquisition of MedImmune83> Cardiovascular of MedImmune83> Financial position, including cash flow and liquidity81> Acquisition of MedImmune83> Financial position, including cash flow and liquidity81> Acquisition of MedImmune<		• •
Goals, strategy and99Performance measurement99Business environment13Business organisation17> Board of Directors at 31 December 200718> Chief Executive Officer, delegation of authority and Senior Executive Team20Our resources, skills and capabilities21> Medicines21> Research and development27> Development pipeline at 31 January 200828> Sales and marketing31> Intellectual property33> Supply and manufacturing33> People36> Main facilities37Corporate governance and managing risk38Cardiovascular (CV) medicines50Gastrointestinal (GI) medicines50Pheople36Oncology medicines50Pinfection medicines61Other businesses66Gographical review77> Measuring performance77> Measuring performance77> Measuring performance77> Measuring performance77> Measuring performance77> Measuring performance78Pinancial review78> Results of operations – summary analysis of year to 31 December 200778> Financial review78> Financial review78> Acquisition and shareholder reture84> Financial review78> Results of operations – summary analysis of year to 31 December 200778 <td>Chief Executive Officer's review</td> <td>05</td>	Chief Executive Officer's review	05
performance measurement09Business environment13Business organisation17> Board of Directors at 31 December 200718> Chief Executive Officer, delegation of authority and Senior Executive Team20Our resources, skills and capabilities21> Medicines21> Medicines21> Research and development23> R&D governance and portfolio management27> Development pipeline at 31 January 200828> Sales and marketing31> Intellectual property33> Supply and manufacturing33> People35> Main facilities37Corporate governance and managing risk38Cardiovascular (CV) medicines50Gastrointestinal (GI) medicines50Neuroscience medicines66Other businesses68Geographical review73Financial review77> Measuring performance77> Measuring performance77> Measuring performance77> Measuring performance77> Measuring performance77> Measuring performance77> Susiness background and major events affecting 200778> Financial review76Financial review73> Capitalisation and shareholder return84> Capitalisation and shareholder return84> Financial review and synergy costs84> Capitalisation and shareholder retur	DIRECTORS' REPORT	08
Business environment13Business organisation17> Board of Directors at 31 December 200718> Chief Executive Officer, delegation of authority and Senior Executive Team20Our resources, skills and capabilities21> Medicines21> Research and development23> R&D governance and portfolio management27> Development pipeline at 31 January 200828> Sales and marketing31> Intellectual property33> Supply and manufacturing33> People35> Main facilities37Corporate governance and managing risk38Cardiovascular (CV) medicines50Gastrointestinal (GI) medicines50Oncology medicines56Oncology medicines69Infection medicines63Infection medicines63Infection medicines63Infection medicines63Infection medicines77> Measuring performance77> Measuring performance77> Measuring performance77> Measuring performance77> Susiness background and major events affecting 200778> Financial review73> Acquisition of MedImmune83> Restructuring and synergy costs84> Financial risk management policies84> Financial risk management policies84> Financial risk management policies84> Capitalisation and sh	Goals, strategy and	
Business organisation17> Board of Directors at 31 December 200718> Chief Executive Officer, delegation of authority and Senior Executive Team20Our resources, skills and capabilities21> Medicines21> Research and development23> R&D governance and portfolio management27> Development pipeline at 31 January 200828> Sales and marketing31> Intellectual property33> Supply and manufacturing33> People35> Main facilities37Corporate governance and managing risk38Cardiovascular (CV) medicines50Gastrointestinal (GI) medicines53Neuroscience medicines56Oncology medicines59Respiratory and Inflammation (R&I) medicines63Infection medicines66Other businesses68Geographical review77> Measuring performance77> Measuring performance77> Measuring performance77> Business background and major events affecting 200778> Results of operations – summary analysis of year to 31 December 200778> Results of operations – summary analysis of year to 31 December 200778> Financial review71> Measuring performance77> Results of operations – summary analysis of year to 31 December 200778> Results of operations – summary analysis of year to 31 December 200778 <td>performance measurement</td> <td>09</td>	performance measurement	09
<ul> <li>Board of Directors at 31 December 2007</li> <li>Shief Executive Officer, delegation of authority and Senior Executive Team</li> <li>Our resources, skills and capabilities</li> <li>Medicines</li> <li>Research and development</li> <li>Research and development</li> <li>Research and development</li> <li>R&amp;D governance and portfolio management</li> <li>R&amp;D governance and portfolio management</li> <li>Development pipeline at 31 January 2008</li> <li>Sales and marketing</li> <li>Intellectual property</li> <li>Supply and manufacturing</li> <li>Supply and the ploticines</li> <li>Supply and the ploticines</li> <li>Supply and the ploticines</li> <li>Supply and the ploticines</li> <li>Supply and the ploting and synergy costs</li> <li>Suply and plo</li></ul>	Business environment	13
31 December 200718> Chief Executive Officer, delegation of authority and Senior Executive Team20Our resources, skills and capabilities21> Medicines21> Research and development23> R&D governance and portfolio management27> Development pipeline at 31 January 200828> Sales and marketing31> Intellectual property33> Supply and manufacturing33> People35> Main facilities37Corporate governance and managing risk38Cardiovascular (CV) medicines50Gastrointestinal (GI) medicines53Neuroscience medicines56Oncology medicines63Infection medicines63Infection medicines63Geographical review75Financial review75Financial review77> Measuring performance77> Measuring performance77> Business background and major events affecting 200778> Financial review71> Seults of operations – summary analysis of year to 31 December 200779> Financial position, including cash flow and liquidity81> Acquisition of MedImmune83> Restructuring and synergy costs84> Future prospects84> Future prospects84> Future prospects84> Critical accounting policies and estimates86> Off-balance sheet transactions,8	Business organisation	17
<ul> <li>Chief Executive Officer, delegation of authority and Senior Executive Team 20</li> <li>Our resources, skills and capabilities 21</li> <li>Medicines 21</li> <li>Research and development 23</li> <li>R&amp;D governance and portfolio management 27</li> <li>Development pipeline at 31 January 2008 28</li> <li>Sales and marketing 31</li> <li>Intellectual property 33</li> <li>Supply and manufacturing 33</li> <li>People 35</li> <li>Main facilities 37</li> <li>Corporate governance and managing risk 38</li> <li>Cardiovascular (CV) medicines 50</li> <li>Gastrointestinal (GI) medicines 53</li> <li>Neuroscience medicines 50</li> <li>Oncology medicines 63</li> <li>Infection medicines 63</li> <li>Infection medicines 63</li> <li>Infection medicines 63</li> <li>Infection medicines 63</li> <li>Geographical review 69</li> <li>In the global community 73</li> <li>Environmental review 77</li> <li>Measuring performance 77</li> <li>Business background and major events affecting 2007 78</li> <li>Results of operations – summary analysis of year to 31 December 2007 79</li> <li>Financial position, including 81</li> <li>Acquisition of MedImmune 83</li> <li>Restructuring and synergy costs 84</li> <li>Capitalisation and shareholder return 84</li> <li>Future prospects 84</li> <li>Scritical accounting policies 86</li> </ul>		10
authority and Senior Executive Team         20           Our resources, skills and capabilities         21           > Medicines         21           > Research and development         23           > R&D governance and portfolio management         27           > Development pipeline at 31 January 2008         28           > Sales and marketing         31           > Intellectual property         33           > Supply and manufacturing         33           > People         35           > Main facilities         37           Corporate governance and managing risk         38           Cardiovascular (CV) medicines         50           Gastrointestinal (GI) medicines         50           Oncology medicines         53           Neuroscience medicines         66           Oncology medicines         63           Infection medicines         66           Other businesses         68           Geographical review         75           Financial review         75           Financial review         77           > Measuring performance         77           > Measuring performance         77           > Measuring performance         77		18
<ul> <li>&gt; Medicines</li> <li>&gt; Research and development</li> <li>&gt; R&amp;D governance and portfolio management</li> <li>&gt; Development pipeline at 31 January 2008</li> <li>&gt; Sales and marketing</li> <li>&gt; Intellectual property</li> <li>&gt; Supply and manufacturing</li> <li>&gt; Supply and manufacturing</li> <li>&gt; Supply and manufacturing</li> <li>&gt; Supply and manufacturing</li> <li>&gt; Main facilities</li> <li></li> <li></li> <li></li></ul>		20
<ul> <li>&gt; Research and development</li> <li>&gt; R&amp;D governance and portfolio management</li> <li>&gt; Development pipeline at 31 January 2008</li> <li>&gt; Sales and marketing</li> <li>&gt; Intellectual property</li> <li>33</li> <li>&gt; Supply and manufacturing</li> <li>&gt; Supply and manufacturing</li> <li>&gt; Main facilities</li> <li>37</li> <li>Corporate governance and managing risk</li> <li>38</li> <li>Cardiovascular (CV) medicines</li> <li>50</li> <li>Gastrointestinal (GI) medicines</li> <li>56</li> <li>Oncology medicines</li> <li>56</li> <li>Oncology medicines</li> <li>57</li> <li>Respiratory and Inflammation (R&amp;I) medicines</li> <li>66</li> <li>Other businesses</li> <li>68</li> <li>Geographical review</li> <li>73</li> <li>Environmental review</li> <li>75</li> <li>Financial review</li> <li>&gt; Measuring performance</li> <li>77</li> <li>&gt; Measuring performance</li> <li>77</li> <li>&gt; Business background and major events affecting 2007</li> <li>78</li> <li>&gt; Results of operations – summary analysis of year to 31 December 2007</li> <li>&gt; Financial position, including cash flow and liquidity</li> <li>Acquisition of MedImmune</li> <li>Acquisition of MedImmune</li> <li>Acquisition and shareholder returm</li> <li>84</li> <li>&gt; Furure prospects</li> <li>84</li> <li>&gt; Financial risk management policies and estimates</li> <li>&gt; Off-balance sheet transactions,</li> </ul>	Our resources, skills and capabilities	21
> R&D governance and portfolio management27> Development pipeline at 31 January 200828> Sales and marketing31> Intellectual property33> Supply and manufacturing33> People35> Main facilities37Corporate governance and managing risk38Cardiovascular (CV) medicines50Gastrointestinal (GI) medicines50Gastrointestinal (GI) medicines50Neuroscience medicines56Oncology medicines59Respiratory and Inflammation (R&I) medicines66Other businesses68Geographical review75Financial review75Financial review77> Measuring performance77> Measuring performance77> Results of operations – summary analysis of year to 31 December 200778> Results of operations – summary analysis of year to 31 December 200779> Financial position, including ccash flow and liquidity81> Acquisition of MedImmune83> Restructuring and synergy costs84> Capitalisation and shareholder return84> Financial risk management policies and estimates86> Off-balance sheet transactions,86		21
portfolio management         27           > Development pipeline at 31 January 2008         28           > Sales and marketing         31           > Intellectual property         33           > People         35           > Main facilities         37           Corporate governance and managing risk         38           Cardiovascular (CV) medicines         50           Gastrointestinal (GI) medicines         56           Oncology medicines         56           Oncology medicines         56           Oncology medicines         63           Infection medicines         66           Other businesses         68           Geographical review         73           Financial review         75           Financial review         77           > Measuring performance         77           > Measuring performance         77           > Measuring performance         77           > Measuring performance         78           > Results of operations – summary analysis of year to 31 December 2007         78           > Results of operations – summary analysis of year to 31 December 2007         79           > Financial position, including cash flow and liquidity         81		23
> Development pipeline at 31 January 2008         28           > Sales and marketing         31           > Intellectual property         33           > People         35           > Main facilities         37           Corporate governance and managing risk         38           Cardiovascular (CV) medicines         50           Gastrointestinal (GI) medicines         56           Oncology medicines         56           Oncology medicines         56           Oncology medicines         63           Infection medicines         63           Geographical review         69           In the global community         73           Environmental review         75           Financial review         77           > Measuring performance         77           > Measuring performance         77           > Measuring performance         77           > Measuring performance         78           > Results of operations – summary analysis of year to 31 December 2007         78           > Results of operations – summary analysis of year to 31 December 2007         79           > Financial position, including cash flow and liquidity         81           > Capitalisation and shareholder reture         84		27
at 31 January 200828> Sales and marketing31> Intellectual property33> Supply and manufacturing33> People35> Main facilities37Corporate governance and managing risk38Cardiovascular (CV) medicines50Gastrointestinal (GI) medicines53Neuroscience medicines56Oncology medicines59Respiratory and Inflammation (R&I) medicines63Infection medicines63Geographical review69In the global community73Environmental review77> Measuring performance77> Measuring performance77> Measuring performance77> Business background and major events affecting 200778> Results of operations – summary analysis of year to 31 December 200779> Financial position, including cash flow and liquidity81> Acquisition of MedImmune83> Restructuring and synergy costs84> Future prospects84> Future prospects84> Critical accounting policies and estimates86> Off-balance sheet transactions,80		21
> Intellectual property33> Supply and manufacturing33> People35> Main facilities37Corporate governance and managing risk38Cardiovascular (CV) medicines50Gastrointestinal (GI) medicines56Oncology medicines56Oncology medicines63Infection medicines63Infection medicines66Other businesses68Geographical review69In the global community73Environmental review77> Measuring performance77> Measuring performance77> Measuring performance77> Results of operations – summary analysis of year to 31 December 200778> Results of operations – summary analysis of year to 31 December 200778> Results of operations – summary analysis of year to 31 December 200778> Financial position, including cash flow and liquidity81> Acquisition of MedImmune83> Restructuring and synergy costs84> Future prospects84> Financial risk management policies and estimates86> Off-balance sheet transactions,80	at 31 January 2008	28
> Supply and manufacturing       33         > People       35         > Main facilities       37         Corporate governance and managing risk       38         Cardiovascular (CV) medicines       50         Gastrointestinal (GI) medicines       53         Neuroscience medicines       56         Oncology medicines       59         Respiratory and Inflammation (R&I) medicines       63         Infection medicines       63         Other businesses       68         Geographical review       69         In the global community       73         Environmental review       75         Financial review       77         > Measuring performance       77         > Measuring performance       77         > Business background and major events affecting 2007       78         > Results of operations – summary analysis of year to 31 December 2007       79         > Financial position, including cash flow and liquidity       81         > Acquisition of MedImmune       83         > Restructuring and synergy costs       84         > Capitalisation and shareholder returm       84         > Future prospects       84         > Critical accounting policies and estimates       <	> Sales and marketing	31
<ul> <li>People</li> <li>Main facilities</li> <li>Main facilities</li> <li>Corporate governance and managing risk</li> <li>38</li> <li>Cardiovascular (CV) medicines</li> <li>Gastrointestinal (GI) medicines</li> <li>Gastrointestinal (GI) medicines</li> <li>Sa</li> <li>Neuroscience medicines</li> <li>Sa</li> <li>Neuroscience medicines</li> <li>Oncology medicines</li> <li>Sa</li> <li>Neuroscience medicines</li> <li>Gastrointestinal (GI) medicines</li> <li>Sa</li> <li>Neuroscience medicines</li> <li>Oncology medicines</li> <li>Sa</li> <li>Neuroscience medicines</li> <li>Gastrointestinal (GI) medicines</li> <li>Sa</li> <li>Neuroscience medicines</li> <li>Gastrointestinal (GI) medicines</li> <li>Sa</li> <li>Neuroscience medicines</li> <li>Gastrointestinal (GI) medicines</li> <li>Measuring medicines</li> <li>Measuring review</li> <li>Neuroscience medicines</li> <li>Neasuring performance</li> <li>Neasuring performance</li> <li>Neasuring performance</li> <li>Neasuring performance</li> <li>Neasuring performance</li> <li>Sa</li> <li>Results of operations – summary analysis of year to 31 December 2007</li> <li>Sinancial position, including cash flow and liquidity</li> <li>Acquisition of MedImmune</li> <li>Restructuring and synergy costs</li> <li>Acapitalisation and shareholder returm</li> <li>Sa</li> <li>Capitalisation and shareholder returm</li> <li>Financial risk management policies</li> <li>Critica</li></ul>	> Intellectual property	33
> Main facilities       37         Corporate governance       38         Cardiovascular (CV) medicines       50         Gastrointestinal (GI) medicines       53         Neuroscience medicines       56         Oncology medicines       59         Respiratory and Inflammation (R&I) medicines       63         Infection medicines       66         Other businesses       68         Geographical review       69         In the global community       73         Environmental review       75         Financial review       77         > Measuring performance       77         > Business background and major events affecting 2007       78         > Results of operations – summary analysis of year to 31 December 2007       79         > Financial position, including cash flow and liquidity       81         > Acquisition of MedImmune       83         > Restructuring and synergy costs       84         > Capitalisation and shareholder return       84         > Future prospects       84         > Financial risk management policies and estimates       86		
Corporate governance and managing risk38Cardiovascular (CV) medicines50Gastrointestinal (GI) medicines53Neuroscience medicines56Oncology medicines59Respiratory and Inflammation (R&I) medicines63Infection medicines63Other businesses68Geographical review69In the global community73Environmental review75Financial review77> Measuring performance77> Measuring performance77> Business background and major events affecting 200778> Results of operations – summary analysis of year to 31 December 200779> Financial position, including cash flow and liquidity81> Acquisition of MedImmune83> Restructuring and synergy costs84> Capitalisation and shareholder return84> Future prospects84> Financial risk management policies and estimates86> Off-balance sheet transactions,80		
and managing risk38Cardiovascular (CV) medicines50Gastrointestinal (GI) medicines53Neuroscience medicines56Oncology medicines59Respiratory and Inflammation (R&I) medicines63Infection medicines66Other businesses68Geographical review73Environmental review75Financial review77> Measuring performance77> Measuring performance77> Measuring performance78> Results of operations – summary analysis of year to 31 December 200779> Financial position, including cash flow and liquidity81> Acquisition of MedImmune83> Restructuring and synergy costs84> Future prospects84> Financial risk management policies and estimates86> Off-balance sheet transactions,86		37
Cardiovascular (CV) medicines50Gastrointestinal (GI) medicines53Neuroscience medicines56Oncology medicines59Respiratory and Inflammation (R&I) medicines63Infection medicines66Other businesses68Geographical review69In the global community73Environmental review77> Measuring performance77> Measuring performance77> Business background and major events affecting 200778> Results of operations – summary analysis of year to 31 December 200779> Financial position, including cash flow and liquidity81> Acquisition of MedImmune83> Restructuring and synergy costs84> Future prospects84> Financial risk management policies and estimates86> Off-balance sheet transactions,86		00
Gastrointestinal (GI) medicines53Neuroscience medicines56Oncology medicines59Respiratory and Inflammation (R&I) medicines63Infection medicines66Other businesses68Geographical review69In the global community73Environmental review75Financial review77> Measuring performance77> Business background and major events affecting 200778> Results of operations – summary analysis of year to 31 December 200779> Financial position, including cash flow and liquidity81> Acquisition of MedImmune83> Restructuring and synergy costs84> Future prospects84> Financial risk management policies and estimates86> Off-balance sheet transactions,80		
Neuroscience medicines56Oncology medicines59Respiratory and Inflammation (R&I) medicines63Infection medicines66Other businesses68Geographical review69In the global community73Environmental review75Financial review77> Measuring performance77> Measuring performance77> Measuring performance77> Results of operations – summary analysis of year to 31 December 200779> Financial position, including cash flow and liquidity81> Acquisition of MedImmune83> Restructuring and synergy costs84> Future prospects84> Financial risk management policies and estimates86> Off-balance sheet transactions,86		
Oncology medicines59Respiratory and Inflammation (R&I) medicines63Infection medicines66Other businesses68Geographical review69In the global community73Environmental review75Financial review77> Measuring performance77> Measuring performance77> Measuring performance77> Measuring performance77> Susiness background and major events affecting 200778> Financial position, including cash flow and liquidity81> Acquisition of MedImmune83> Restructuring and synergy costs84> Capitalisation and shareholder return84> Future prospects84> Financial risk management policies and estimates86> Off-balance sheet transactions,86	. ,	
Respiratory and Inflammation (R&I) medicines       63         Infection medicines       66         Other businesses       68         Geographical review       69         In the global community       73         Environmental review       75         Financial review       77         > Measuring performance       77         > Business background and major events affecting 2007       78         > Results of operations – summary analysis of year to 31 December 2007       79         > Financial position, including cash flow and liquidity       81         > Acquisition of MedImmune       83         > Restructuring and synergy costs       84         > Capitalisation and shareholder return       84         > Future prospects       84         > Financial risk management policies and estimates       86	Neuroscience medicines	
(R&I) medicines63Infection medicines66Other businesses68Geographical review69In the global community73Environmental review75Financial review77> Measuring performance77> Measuring performance77> Business background and major events affecting 200778> Results of operations – summary analysis of year to 31 December 200779> Financial position, including cash flow and liquidity81> Acquisition of MedImmune83> Restructuring and synergy costs84> Capitalisation and shareholder return84> Financial risk management policies and estimates86> Off-balance sheet transactions,86	Oncology medicines	59
Infection medicines66Other businesses68Geographical review69In the global community73Environmental review75Financial review77> Measuring performance77> Measuring performance77> Measuring performance77> Business background and major events affecting 200778> Results of operations – summary analysis of year to 31 December 200779> Financial position, including cash flow and liquidity81> Acquisition of MedImmune83> Restructuring and synergy costs84> Capitalisation and shareholder return84> Future prospects84> Financial risk management policies 		63
Other businesses68Geographical review69In the global community73Environmental review75Financial review77> Measuring performance77> Measuring performance77> Business background and major events affecting 200778> Results of operations – summary analysis of year to 31 December 200779> Financial position, including cash flow and liquidity81> Acquisition of MedImmune83> Restructuring and synergy costs84> Future prospects84> Financial risk management policies and estimates86> Off-balance sheet transactions,86		66
Geographical review       69         In the global community       73         Environmental review       75         Financial review       77         > Measuring performance       77         > Measuring performance       77         > Business background and major events affecting 2007       78         > Results of operations – summary analysis of year to 31 December 2007       79         > Financial position, including cash flow and liquidity       81         > Acquisition of MedImmune       83         > Restructuring and synergy costs       84         > Future prospects       84         > Financial risk management policies and estimates       86         > Off-balance sheet transactions,       86		
In the global community       73         Environmental review       75         Financial review       77         > Measuring performance       77         > Business background and major events affecting 2007       78         > Results of operations – summary analysis of year to 31 December 2007       79         > Financial position, including cash flow and liquidity       81         > Acquisition of MedImmune       83         > Restructuring and synergy costs       84         > Capitalisation and shareholder return       84         > Future prospects       84         > Financial risk management policies and estimates       85         > Off-balance sheet transactions,       86		
Environmental review       75         Financial review       77         > Measuring performance       77         > Business background and major events affecting 2007       78         > Results of operations – summary analysis of year to 31 December 2007       79         > Financial position, including cash flow and liquidity       81         > Acquisition of MedImmune       83         > Restructuring and synergy costs       84         > Capitalisation and shareholder return       84         > Future prospects       84         > Financial risk management policies and estimates       86         > Off-balance sheet transactions,       86		
Financial review       77         > Measuring performance       77         > Business background and major events affecting 2007       78         > Results of operations – summary analysis of year to 31 December 2007       79         > Financial position, including cash flow and liquidity       81         > Acquisition of MedImmune       83         > Restructuring and synergy costs       84         > Future prospects       84         > Financial risk management policies and estimates       86         > Off-balance sheet transactions,       86	° ,	
<ul> <li>Measuring performance</li> <li>Business background and major events affecting 2007</li> <li>Results of operations – summary analysis of year to 31 December 2007</li> <li>Financial position, including cash flow and liquidity</li> <li>Acquisition of MedImmune</li> <li>Restructuring and synergy costs</li> <li>Restructuring and synergy costs</li> <li>Future prospects</li> <li>Financial risk management policies and estimates</li> <li>Off-balance sheet transactions,</li> </ul>		
<ul> <li>&gt; Business background and major events affecting 2007 78</li> <li>&gt; Results of operations – summary analysis of year to 31 December 2007 79</li> <li>&gt; Financial position, including cash flow and liquidity 81</li> <li>&gt; Acquisition of MedImmune 83</li> <li>&gt; Restructuring and synergy costs 84</li> <li>&gt; Capitalisation and shareholder return 84</li> <li>&gt; Future prospects 84</li> <li>&gt; Financial risk management policies 85</li> <li>&gt; Critical accounting policies and estimates 86</li> <li>&gt; Off-balance sheet transactions,</li> </ul>		
<ul> <li>Results of operations – summary analysis of year to 31 December 2007 79</li> <li>Financial position, including cash flow and liquidity 81</li> <li>Acquisition of MedImmune 83</li> <li>Restructuring and synergy costs 84</li> <li>Capitalisation and shareholder return 84</li> <li>Future prospects 84</li> <li>Financial risk management policies 85</li> <li>Critical accounting policies and estimates 86</li> <li>Off-balance sheet transactions,</li> </ul>	> Business background and	11
analysis of year to 31 December 2007 79> Financial position, including cash flow and liquidity81> Acquisition of MedImmune83> Restructuring and synergy costs84> Capitalisation and shareholder return84> Future prospects84> Financial risk management policies and estimates86> Off-balance sheet transactions,		78
cash flow and liquidity81> Acquisition of MedImmune83> Restructuring and synergy costs84> Capitalisation and shareholder return84> Future prospects84> Financial risk management policies85> Critical accounting policies and estimates86> Off-balance sheet transactions,	<ul> <li>Results of operations – summary analysis of year to 31 December 2007</li> </ul>	79
<ul> <li>&gt; Acquisition of MedImmune</li> <li>&gt; Restructuring and synergy costs</li> <li>&gt; Capitalisation and shareholder return</li> <li>&gt; Future prospects</li> <li>&gt; Financial risk management policies</li> <li>&gt; Critical accounting policies         <ul> <li>and estimates</li> <li>&gt; Off-balance sheet transactions,</li> </ul> </li> </ul>	<ul> <li>Financial position, including cash flow and liquidity</li> </ul>	81
<ul> <li>&gt; Restructuring and synergy costs</li> <li>&gt; Capitalisation and shareholder return</li> <li>&gt; Future prospects</li> <li>&gt; Financial risk management policies</li> <li>&gt; Critical accounting policies         <ul> <li>and estimates</li> <li>&gt; Off-balance sheet transactions,</li> </ul> </li> </ul>		
<ul> <li>&gt; Capitalisation and shareholder return 84</li> <li>&gt; Future prospects 84</li> <li>&gt; Financial risk management policies 85</li> <li>&gt; Critical accounting policies and estimates 86</li> <li>&gt; Off-balance sheet transactions,</li> </ul>		
<ul> <li>&gt; Financial risk management policies 85</li> <li>&gt; Critical accounting policies and estimates 86</li> <li>&gt; Off-balance sheet transactions,</li> </ul>		84
<ul> <li>&gt; Critical accounting policies and estimates</li> <li>&gt; Off-balance sheet transactions,</li> </ul>		84
and estimates 86 > Off-balance sheet transactions,		85
		86
	<ul> <li>&gt; Off-balance sheet transactions, contingent liabilities and commitments</li> </ul>	90

DOCKET

ALARM

	ew accounting standards	92
	arbanes-Oxley Act section 404	92
	esults of operations – summary nalysis of year to 31 December 2006	6 93
> Fi	inancial position, including	
Ca	ash flow and liquidity – 2006	95
DEMU		00
REMUI	NERATION REPORT	98
FINAN	CIAL STATEMENTS	116
Prepa	aration of the Financial	
	ments and Directors'	
respo	onsibilities	116
	tors' responsibilities for,	
	eport on, internal control	
	financial reporting	116
	· · ·	110
	ors' reports on the Financial	
	ments and on internal control	
	financial reporting	117
•	anes-Oxley Act section 404)	117
	endent auditors'	
•	t to the members of	
Astra	Zeneca PLC (Group)	117
Conso	olidated income statement	118
Conso	olidated statement of	
recog	inised income and expense	118
-	-	119
Coner	nunated palance sheet	
	olidated balance sheet	
Conse	olidated cash flow statement	120
Conse		
Conso Accou	olidated cash flow statement	120
Conso Accou Notes	olidated cash flow statement unting policies (Group)	120
Conso Accou Notes State	olidated cash flow statement unting policies (Group) s to the Financial	120 121
Conso Accou Notes Stater	olidated cash flow statement unting policies (Group) s to the Financial ments (Group)	120 121 124
Conso Accou Notes States 1 ( 2 F	olidated cash flow statement unting policies (Group) s to the Financial ments (Group) Operating profit Restructuring and synergy costs	120 121 124 124
Conso Accou Notes States 1 ( 2 F 3 F	olidated cash flow statement unting policies (Group) s to the Financial ments (Group) Operating profit	<b>120</b> <b>121</b> <b>124</b> 124 124
Conse Accou Notes State 1 ( 2 F 3 F 4 7	olidated cash flow statement unting policies (Group) s to the Financial ments (Group) Operating profit Restructuring and synergy costs Finance income and expense Taxation	<b>120</b> <b>121</b> <b>124</b> 124 124 125 125
Conso Accou Notes Stater 1 ( 2 F 3 F 4 T 5 E	olidated cash flow statement unting policies (Group) s to the Financial ments (Group) Operating profit Restructuring and synergy costs Finance income and expense Taxation Earnings per \$0.25 Ordinary Share	<b>120</b> <b>121</b> <b>124</b> 124 124 125 125 127
Conso Accou Notes Stater 1 ( 2 F 3 F 4 T 5 E 6 S	olidated cash flow statement unting policies (Group) s to the Financial ments (Group) Operating profit Restructuring and synergy costs Finance income and expense Faxation Earnings per \$0.25 Ordinary Share Segment information	<b>120</b> <b>121</b> <b>124</b> 124 124 125 125 127 128
Conso Accou Notes Stater 1 ( 2 F 3 F 4 T 5 E 6 S 7 F	olidated cash flow statement unting policies (Group) s to the Financial ments (Group) Operating profit Restructuring and synergy costs Finance income and expense Faxation Earnings per \$0.25 Ordinary Share Segment information Product sales information	<b>120</b> <b>121</b> <b>124</b> 124 124 125 125 125 127 128 130
Conso Accou Notes Stater 1 ( 2 F 3 F 4 7 5 E 6 S 7 F 8 F	olidated cash flow statement unting policies (Group) s to the Financial ments (Group) Operating profit Restructuring and synergy costs Finance income and expense Taxation Earnings per \$0.25 Ordinary Share Begment information Product sales information Property, plant and equipment	<b>120</b> <b>121</b> <b>124</b> 124 124 125 125 127 128 130 131
Conso Accou Notes Stater 1 ( 2 F 3 F 4 T 5 E 6 S 7 F 8 F 9 (	olidated cash flow statement unting policies (Group) s to the Financial ments (Group) Dperating profit Restructuring and synergy costs Finance income and expense Taxation Earnings per \$0.25 Ordinary Share Segment information Product sales information Property, plant and equipment Goodwill	<b>120</b> <b>121</b> <b>124</b> 124 125 125 125 127 128 130 131 132
Conso Accou Notes Stater 1 ( 2 F 3 F 4 T 5 E 6 S 7 F 8 F 9 ( 10 II	olidated cash flow statement unting policies (Group) s to the Financial ments (Group) Dperating profit Restructuring and synergy costs Finance income and expense Taxation Earnings per \$0.25 Ordinary Share Segment information Product sales information Property, plant and equipment Goodwill ntangible assets	<b>120</b> <b>121</b> <b>124</b> <b>124</b> <b>125</b> <b>125</b> <b>127</b> <b>128</b> <b>130</b> <b>131</b> <b>132</b> <b>133</b>
Conso Accou Notes Stater 1 ( 2 F 3 F 4 T 5 E 6 § 7 F 8 F 9 ( 10 II 11 (	olidated cash flow statement unting policies (Group) s to the Financial ments (Group) Operating profit Restructuring and synergy costs Finance income and expense Taxation Earnings per \$0.25 Ordinary Share Segment information Product sales information Property, plant and equipment Goodwill ntangible assets Other investments	<b>120</b> <b>121</b> <b>124</b> <b>124</b> <b>125</b> <b>127</b> <b>128</b> <b>130</b> <b>131</b> <b>132</b> <b>133</b> <b>134</b>
Conso Accou Notes Stater 1 ( 2 F 3 F 4 T 5 E 6 S 7 F 8 F 9 ( 10 li 11 ( 12 li	olidated cash flow statement unting policies (Group) s to the Financial ments (Group) Operating profit Restructuring and synergy costs Finance income and expense Taxation Earnings per \$0.25 Ordinary Share Begment information Product sales information Property, plant and equipment Goodwill ntangible assets Other investments nventories	<b>120</b> <b>121</b> <b>124</b> <b>124</b> <b>125</b> <b>125</b> <b>125</b> <b>125</b> <b>125</b> <b>127</b> <b>128</b> <b>130</b> <b>131</b> <b>132</b> <b>133</b> <b>134</b> <b>134</b>
Conso Accou Notes Stater 1 ( 2 F 3 F 4 T 5 E 6 S 7 F 8 F 9 ( 10 II 11 ( 12 II 13 T	olidated cash flow statement unting policies (Group) s to the Financial ments (Group) Operating profit Restructuring and synergy costs Finance income and expense Faxation Farnings per \$0.25 Ordinary Share Begment information Product sales information Product sales information Property, plant and equipment Goodwill ntangible assets Other investments nventories Frade and other receivables	<b>120</b> <b>121</b> <b>124</b> <b>124</b> <b>125</b> <b>125</b> <b>125</b> <b>127</b> <b>128</b> <b>130</b> <b>131</b> <b>132</b> <b>133</b> <b>134</b> <b>134</b> <b>135</b>
Conso Accou Notes Stater 1 ( 2 F 3 F 4 T 5 E 6 S 7 F 8 F 9 ( 10 li 11 ( 12 li 13 T 14 (	olidated cash flow statement unting policies (Group) s to the Financial ments (Group) Operating profit Restructuring and synergy costs Finance income and expense Taxation Earnings per \$0.25 Ordinary Share Segment information Product sales information Product sales information Property, plant and equipment Goodwill ntangible assets Other investments nventories Trade and other receivables Cash and cash equivalents	<b>120</b> <b>121</b> <b>124</b> <b>124</b> <b>125</b> <b>125</b> <b>125</b> <b>125</b> <b>125</b> <b>127</b> <b>128</b> <b>130</b> <b>131</b> <b>132</b> <b>133</b> <b>134</b> <b>134</b>
Conso Accou Notes Stater 1 ( 2 F 3 F 4 T 5 E 6 S 7 F 8 F 9 ( 10 li 11 ( 12 li 13 T 14 ( 15 li 2 c 15 li 2 c 10 li 13 T 14 ( 2 c 1 c 1 c 2 c 2 c 1 c 2 c 1 c 2 c 1 c 2 c 1 c 2 c 1 c 2 c 1 c 2 c 2 c 2 c 1 c 2	olidated cash flow statement unting policies (Group) s to the Financial ments (Group) Derating profit Restructuring and synergy costs Finance income and expense Taxation Earnings per \$0.25 Ordinary Share Segment information Product sales information Product sales information Property, plant and equipment Goodwill ntangible assets Other investments nventories Trade and other receivables Cash and cash equivalents nterest bearing loans and borrowings	<b>120</b> <b>121</b> <b>124</b> <b>124</b> <b>125</b> <b>125</b> <b>125</b> <b>127</b> <b>128</b> <b>130</b> <b>131</b> <b>132</b> <b>133</b> <b>134</b> <b>134</b> <b>135</b>
Conso Accou Notes Stater 1 ( 2 F 3 F 4 T 5 E 6 S 7 F 8 F 9 ( 10 li 11 ( 12 li 13 T 14 ( 15 li 23 T 14 ( 15 li 23 T 14 ( 15 li 23 T 14 ( 16 S	olidated cash flow statement unting policies (Group) s to the Financial ments (Group) Derating profit Restructuring and synergy costs Finance income and expense Taxation Earnings per \$0.25 Ordinary Share Segment information Product sales information Product sales information Property, plant and equipment Goodwill ntangible assets Other investments nventories Trade and other receivables Cash and cash equivalents nterest bearing loans and borrowings Financial risk management	<b>120</b> <b>121</b> <b>124</b> <b>124</b> <b>125</b> <b>125</b> <b>127</b> <b>128</b> <b>130</b> <b>131</b> <b>132</b> <b>133</b> <b>134</b> <b>134</b> <b>135</b> <b>135</b>
Conso Accou Notes Stater 1 ( 2 F 3 F 4 T 5 E 6 S 7 F 8 F 9 ( 10 li 11 ( 12 li 13 T 14 ( 15 li 2 li 13 T 14 ( 15 li 2 li 14 ( 15 li 2 li 13 T	olidated cash flow statement unting policies (Group) s to the Financial ments (Group) Derating profit Restructuring and synergy costs Finance income and expense Taxation Earnings per \$0.25 Ordinary Share Segment information Product sales information Pr	120           121           124           125           125           127           128           130           131           132           133           134           135           136
Conso Accou Notes Stater 1 ( 2 F 3 F 4 T 5 E 6 S 7 F 8 F 9 ( 10 In 11 ( 12 In 13 T 14 ( 15 In 2 In 16 F ( 0 C 17 F	olidated cash flow statement unting policies (Group) s to the Financial ments (Group) Derating profit Restructuring and synergy costs Finance income and expense Taxation Earnings per \$0.25 Ordinary Share Segment information Product sales information Protect sales information Pr	<b>120</b> <b>121</b> <b>124</b> <b>124</b> <b>125</b> <b>125</b> <b>125</b> <b>127</b> <b>128</b> <b>130</b> <b>131</b> <b>132</b> <b>133</b> <b>134</b> <b>135</b> <b>135</b> <b>135</b> <b>136</b> <b>138</b>
Conso Accou Notes Stater 1 ( 2 F 3 F 4 T 5 E 6 S 7 F 8 F 9 ( 10 In 11 ( 12 In 13 T 14 ( 15 In 2 In 14 ( 15 In 14 ( 15 In 14 ( 15 In 16 In 17 In 18 T	olidated cash flow statement unting policies (Group) s to the Financial ments (Group) Derating profit Restructuring and synergy costs Finance income and expense Taxation Earnings per \$0.25 Ordinary Share Segment information Product sales information Proterty, plant and equipment Goodwill ntangible assets Dther investments nventories Trade and other receivables Cash and cash equivalents nterest bearing loans and borrowings Financial risk management objectives and policies Financial instruments Trade and other payables	120           121           124           125           125           125           127           128           130           131           132           133           134           135           135           136           138           142
Conso Accou Notes Stater 1 ( 2 F 3 F 4 T 5 E 6 S 7 F 8 F 9 ( 10 II 11 ( 12 II 13 T 14 ( 15 II) 2 II 14 ( 15 II) 14 ( 15 II) 14 ( 16 II) 14 ( 17 II) 14 (17 II) 14 (17 II) 14 (17 II) 14 (17 II) 14 (	olidated cash flow statement unting policies (Group) s to the Financial ments (Group) Derating profit Restructuring and synergy costs Finance income and expense Taxation Earnings per \$0.25 Ordinary Share Segment information Product sales information Protect sales information Protectives and policies Financial instruments Trade and other payables Provisions for liabilities and charges	120           121           124           125           125           125           127           128           130           131           132           133           134           135           135           136           138           142
Conso Accou Notes Stater 1 ( 2 F 3 F 4 T 5 E 6 S 7 F 8 F 9 ( 10 II 11 ( 12 II 13 T 14 ( 15 II) 2 II 14 ( 15 II) 14 ( 15 II) 14 ( 16 II) 14 ( 17 II) 14 (17 II) 14 (17 II) 14 (17 II) 14 (17 II) 14 (	olidated cash flow statement unting policies (Group) s to the Financial ments (Group) Derating profit Restructuring and synergy costs Finance income and expense Taxation Earnings per \$0.25 Ordinary Share Segment information Product sales information Proterty, plant and equipment Goodwill ntangible assets Dther investments nventories Trade and other receivables Cash and cash equivalents nterest bearing loans and borrowings Financial risk management objectives and policies Financial instruments Trade and other payables	120           121           124           125           125           125           127           128           130           131           132           133           134           135           135           136           138           142
Conso Accou Notes Stater 1 C 2 F 3 F 4 T 5 E 6 S 7 F 8 F 9 C 10 II 11 C 12 II 13 T 14 C 12 II 14 C 12 II 14 C 12 II 14 C 12 II 14 C 12 II 14 C 12 II 14 C 14 T 15 E 16 S 16 S 16 S 17 F 16 S 17 F 16 S 17 F 17 F 17 F 17 C 17 F 17 F 17 F 17 F 17 F 17 F 17 F 17 F	olidated cash flow statement unting policies (Group) s to the Financial ments (Group) Derating profit Restructuring and synergy costs Finance income and expense Taxation Earnings per \$0.25 Ordinary Share Segment information Product sales information Protect sales information Protectives and policies Financial instruments Trade and other payables Provisions for liabilities and charges	120           121           124           125           125           127           128           130           131           132           133           134           135           136           138           142
Conso Accou Notes Stater 1 ( 2 F 3 F 4 T 5 E 6 S 7 F 8 F 9 ( 10 II 11 ( 12 II 13 T 14 ( 15 II 14 ( 16 II 14 ( 16 II 14 ( 16 II 14 ( 16 II 14 ( 17 II 14 ( 16 II 14 ( 17 II 14 ( 16 II 14 ( 16 II 14 ( 16 II 14 ( 17 II 14 ( 17 II 14 ( 16 II 14 ( 16 II 14 ( 17 II 14 ( 16 II 14 ( 17 II 14 ( 16 II 14 ( 16 II 14 ( 17 II 14 ( 16 II 14 ( 17 II 14 ( 16 II 16 II 16 II 17 II 18 T 19 F 20 S 21 F	olidated cash flow statement unting policies (Group) s to the Financial ments (Group) Dperating profit Restructuring and synergy costs Finance income and expense Taxation Earnings per \$0.25 Ordinary Share Segment information Product sales information Product sales information Property, plant and equipment Goodwill ntangible assets Dther investments nventories Trade and other receivables Cash and cash equivalents nterest bearing loans and borrowings Financial risk management objectives and policies Financial instruments Trade and other payables Provisions for liabilities and charges Statement of changes in equity	120           121           124           124           124           125           127           128           130           131           132           133           134           135           136           138           142           142           142           142
Conso Accou Notes Stater 1 ( 2 F 3 F 4 T 5 E 6 S 7 F 8 F 9 ( 10 II 11 ( 12 II 13 T 14 ( 15 II 19 F 20 S 21 F 22 N	olidated cash flow statement unting policies (Group) s to the Financial ments (Group) Dperating profit Restructuring and synergy costs Finance income and expense Taxation Earnings per \$0.25 Ordinary Share Segment information Product sales information Product sales information Property, plant and equipment Goodwill ntangible assets Dther investments nventories Trade and other receivables Cash and cash equivalents nterest bearing loans and borrowings Financial risk management objectives and policies Financial instruments Trade and other payables Provisions for liabilities and charges Statement of changes in equity Reserves	120           121           124           124           125           125           127           128           130           131           132           133           134           135           136           138           142           143           144

> International accounting transition

92 92

	oyee costs and share option for employees	153
	mitments and	
	ngent liabilities	158
28 Lease	es	174
29 Statu	tory and other information	175
30 Share	e capital of parent company	176
Principal s	subsidiaries	177
Independe	ent auditors'	
report to t	he members of	
AstraZene	eca PLC (Company)	178
Company	balance sheet	179
Accountin	ig policies (Company)	180
Notes to t	he Financial	
Statement	ts (Company)	181
1 Fixed	asset investments	181
2 Other	r debtors	181
3 Non-	trade creditors	181
4 Loan	S	181
5 Rese	rves	182
	nciliation of movement in holders' funds	182
7 Share	e capital	182
	mitments and	
	ngent liabilities	183
9 Statu	tory and other information	183
Group fina	ancial record	184
ADDITIONA	L INFORMATION	186
Sharehold	ler information	186

ADDITIONAL INFORMATION	186
Shareholder information	186
Risk	193
Corporate information	200
Cross-reference to Form 20-F	201
Glossary	202

## Cautionary statement regarding forward-looking statements

The purpose of this Annual Report and Form 20-F Information is to provide information to the members of the Company. In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995 and the UK Companies Act 2006, we are providing the following cautionary statement: This Annual Report and Form 20-F Information contains certain forwardlooking statements with respect to the operations, performance and financial condition of the Group. Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forwardlooking statements reflect knowledge and information available at the date of the preparation of this Annual Report and Form 20-F Information and the Company undertakes no obligation to update these forwardlooking statements. We identify the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond our control, include, among other things, those factors identified in the section 'Risk' on pages 193 to 199 of this document. Nothing in this Annual Report and Form 20-F Information should be construed as a profit forecast.

## ASTRAZENECA AND OUR YEAR IN BRIEF

DOCKE

ASTRAZENECA IS ONE OF THE WORLD'S LEADING PHARMACEUTICAL COMPANIES WITH A BROAD RANGE OF MEDICINES DESIGNED TO FIGHT DISEASE IN IMPORTANT AREAS OF HEALTHCARE. BACKED BY STRONG SCIENCE AND WIDE-RANGING COMMERCIAL SKILLS, WE ARE COMMITTED TO SUSTAINABLE DEVELOPMENT OF OUR BUSINESS AND THE DELIVERY OF A FLOW OF NEW MEDICINES THAT BRING BENEFIT FOR PATIENTS AND CREATE ENDURING VALUE FOR OUR SHAREHOLDERS AND SOCIETY.

### 2007 IN BRIEF

- > Sales up 7% to \$29,559 million.
- > Crestor sales up 33% to \$2,796 million; Symbicort up 22% to \$1,575 million; Seroquel up 15% to \$4,027 million; and Arimidex up 10% to \$1,730 million. Nexium sales down 2% to \$5,216 million.
- > Our product portfolio now includes 11 medicines with annual sales of more than \$1 billion each.
- > Sales up 17% in emerging markets.
- > Operating profit (excluding restructuring and synergy costs) up 8% to \$9,060 million.
- > Cash distributions to shareholders totalled \$6,811 million (dividends \$2,641 million; share re-purchases \$4,170 million).
- > Earnings per share (excluding restructuring and synergy costs) were \$4.20, ahead of target.
- > Dividend up 9% to \$1.87 for the full year.
- > Investment in R&D increased to more than \$5 billion.
- > A record 36 new compounds were selected for development and 24 compounds progressed to first human exposure. Phase III development pipeline doubled from five to 10 projects.
- > Over 20 major externalisation deals and two significant acquisitions in the past two years.
- > Acquisition of MedImmune in June 2007 established us as a leader in biotechnology amongst our pharmaceutical peers.
- > Productivity initiatives, including restructuring programme, progressing to plan.

## **FINANCIAL HIGHLIGHTS**

Growth rates represent underlying performance, which shows growth at constant exchange rates (CER) by excluding the effects of exchange rate movements. Underlying CER growth is calculated by retranslating the current year's performance at the previous year's exchange rates and adjusting for other exchange effects, including hedging.

DOCKET


RM


Δ





EARNINGS PER ORDINARY SHARE \$			
		GROWTH	
<b>07</b> <sup>1</sup>	4.20	+7%	
07	3.74	-5%	
06	3.86	+34%	
05	2.91	+41%	





SG&A COSTS \$M		
		GROWTH
071	9,886	+4%
07	10,364	+9%
06	9,096	+5%
05	8,695	+4%

	HAREHOLDERS – ) Share Re-Purchases \$M
07	6,811
06	6,367
05	4,718

<sup>1</sup> Excluding restructuring and synergy costs.

Find authenticated court documents without watermarks at docketalarm.com.

NEXIUM -2%		SEROQUEL +15%	CRESTOR +33%
		SENUQUEL + 13%	UNE3/UN +33%
07	5,216	07 4,027	07 2,796
06	5,182	06 3,416	06 2,028
05	4,633	05 2,761	05 1,268
ARIMIDEX +10%		SYMBICORT +22%	PULMICORT +10%
07 1,730		07 1,575	07 1,454
06 1,508		06 1,184	06 1,292
05 1,181		05 1,006	05 1,162
SELOKEN/TOPROL-XL -22%		CASODEX+6%	ATACAND +9%
07 1,438		07 1,335	07 1,287
06 1,795		06 1,206	06 1,110
05 1,735		05 1,123	05 974
LOSEC/PRILOSEC -20%		ZOLADEX +4%	MERREM +20%
07 1,143		07 1,104	07 773
06 1,371		06 1,008	06 604
05 1,652		05 1,004	05 505
SYNAGIS <sup>1</sup>		FLUMIST <sup>1</sup>	
07 618		07 53	

<sup>1</sup> Sales of MedImmune products are consolidated in AstraZeneca accounts from 1 June 2007. As a result, there are no prior period sales included.

DIVIDEND FOR 2007				
	\$	Pence	SEK	Payment date
First interim dividend	0.52	25.3	3.49	17 September 2007
Second interim dividend	1.35	67.7	8.61	17 March 2008
Total	1.87	93.0	12.10	

# DOCKET A L A R M



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

### E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.